Patents by Inventor Gregorio Asensio Aguilar

Gregorio Asensio Aguilar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combine use of pterostilbene and quercetin for the production of cancer treatment medicaments
    Patent number: 8227510
    Abstract: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 ?M)+QUER(20 ?M) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg× day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: July 24, 2012
    Assignee: Universitat de Valencia
    Inventors: José María Estrela Ariquel, Gregorio Asensio Aguilar, Miguel Angel Asensi Miralles, Elena Obrador Plá, Maria Teresa Varea Muñoz, Leonardo Jordá Quilis, Paula Ferrer Pastor, Ramón Segarra Guerrero, Angel Ortega Valero, Maria Benlloch Garcia
  • COMBINE USE OF PTEROSTILBENE AND QUERCETIN FOR THE PRODUCTION OF CANCER TREATMENT MEDICAMENTS
    Publication number: 20110224290
    Abstract: The invention relates to the combined use of pterostilbene and quercetin for the production of cancer treatment medicaments. The in vitro growth of melanoma cells B16-F10 (B16M-F10) is inhibited (56%) by combined exposures of short duration (60 min/day) to PTER (40 ?M)+QUER (20 ?M) (˜average values of plasma concentrations measured within the first hour following the IV administration of 20 mg of each polyphenol/kg ˜). The combined intravenous administration of PTER+QUER (20 mg/kg×day) to mice inhibits (73%) the metastatic growth of melanoma B16M-F10 in the liver, a common site for metastasis development. The invention demonstrates that the combination of PTER+QUER inhibits the growth of malignant melanoma metastasis and prolongs the survival of the carrier host.
    Type: Application
    Filed: July 19, 2005
    Publication date: September 15, 2011
    Inventors: José Maria Estrela Ariquel, Gregorio Asensio Aguilar, Miguel Angel Asensi Miralles, Elena Obrador Plá, Maria Teresa Varea Munoz, Leonardo Jordá Quilis, Paula Ferrer Pastor, Ramón Segarra Guerrero, Angel Ortega Valero, Maria Benlloch Garcia